[1]ReinDB, StevensGA, TheakerJ, et al. The global burden of hepatitis E virus genotypes 1 and 2 in 2005[J]. Hepatology, 2012, 55(4): 988-997. DOI: 10.1002/hep.25505.
[2]PischkeS, HartlJ, PasSD, et al. Hepatitis E virus: infection beyond the liver?[J]. J Hepatol, 2017, 66(5): 1082-1095. DOI: 10.1016/j.jhep.2016.11.016.
[3]AggarwalR. Hepatitis E: clinical presentation in disease-endemic areas and diagnosis[J]. Semin Liver Dis, 2013, 33(1): 30-40. DOI: 10.1055/s-0033-1338112.
[4]NimgaonkarI, DingQ, SchwartzRE, et al. Hepatitis E virus: advances and challenges[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(2): 96-110. DOI: 10.1038/nrgastro.2017.150.
[5]LenggenhagerD, WeberA. Hepatitis E virus and the liver: clinical settings and liver pathology[J]. Gastroenterol Clin North Am, 2017, 46(2): 393-407. DOI: 10.1016/j.gtc.2017.01.010.
[6]KamarN, BendallR, Legrand-AbravanelF, et al. Hepatitis E[J]. Lancet, 2012, 379(9835): 2477-2488. DOI: 10.1016/S0140-6736(11)61849-7.
[7]DaltonHR, StableforthW, ThurairajahP, et al. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease[J]. Eur J Gastroenterol Hepatol, 2008, 20(8): 784-790. DOI: 10.1097/MEG.0b013e3282f5195a.
[8]WangYJ, LiuHY, LiuSH, et al. Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: a tertiary nested case-control study[J]. Liver Int, 2019, 39(12): 2291-2300. DOI: 10.1111/liv.14221.
[9]LhommeS, MarionO, AbravanelF, et al. Clinical manifestations, pathogenesis and treatment of hepatitis E virus infections[J]. J Clin Med, 2020, 9(2). DOI: 10.3390/jcm9020331.
[10]AslanAT, BalabanHY. Hepatitis E virus: Epidemiology, diagnosis, clinical manifestations, and treatment[J]. World J Gastroenterol, 2020, 26(37): 5543-5560. DOI: 10.3748/wjg.v26.i37.5543.
[11]中华医学会肝病学分会 . 戊型肝炎防治共识[J]. 中华肝脏病杂志 , 2022, 30(8): 820-831. DOI: 10.3760/cma.j.cn501113-20220729-00401.
[12]PeronJM, BureauC, PoirsonH, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy[J]. J Viral Hepat, 2007, 14(5): 298-303. DOI: 10.1111/j.1365-2893.2007.00858.x.
[13]KumarA, SaraswatVA. Hepatitis E and acute-on-chronic liver failure[J]. J Clin Exp Hepatol, 2013, 3(3): 225-230. DOI: 10.1016/j.jceh.2013.08.013.
[14]Blasco-PerrinH, MaddenRG, StanleyA, et al. Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study[J]. Aliment Pharmacol Ther, 2015, 42(5): 574-581. DOI: 10.1111/apt.13309.
[15]KumarAS, KumarSP, SinghR, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death[J]. J Hepatol, 2007, 46(3): 387-394. DOI: 10.1016/j.jhep.2006.09.016.
[16]HamidSS, AtiqM, ShehzadF, et al. Hepatitis E virus superinfection in patients with chronic liver disease[J]. Hepatology, 2002, 36(2): 474-478. DOI: 10.1053/jhep.2002.34856.
[17]RamachandranJ, EapenCE, KangG, et al. Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease[J]. J Gastroenterol Hepatol, 2004, 19(2): 134-138. DOI: 10.1111/j.1440-1746.2004.03188.x.
[18]AggarwalR, GoelA. Natural history, clinical manifestations, and pathogenesis of hepatitis E virus genotype 1 and 2 infections[J]. Cold Spring Harb Perspect Med, 2019, 9(7). DOI: 10.1101/cshperspect.a032136.
[19]Shalimar, KediaS, MahapatraSJ, et al. Severity and outcome of acute-on-chronic liver failure is dependent on the etiology of acute hepatic insults: analysis of 368 patients[J]. J Clin Gastroenterol, 2017, 51(8): 734-741. DOI: 10.1097/MCG.0000000000000823.
[20]KhurooMS, KamiliS. Aetiology and prognostic factors in acute liver failure in India[J]. J Viral Hepat, 2003, 10(3): 224-231. DOI: 10.1046/j.1365-2893.2003.00415.x.
[21]MaZ, De ManRA, KamarN, et al. Chronic hepatitis E: advancing research and patient care[J]. J Hepatol, 2022, 77(4): 1109-1123. DOI: 10.1016/j.jhep.2022.05.006.
[22]Von FeldenJ, AlricL, PischkeS, et al. The burden of hepatitis E among patients with haematological malignancies: a retrospective European cohort study[J]. J Hepatol, 2019, 71(3): 465-472. DOI: 10.1016/j.jhep.2019.04.022.
[23]Di BartolomeoS, CarubbiF, CiprianiP. Hepatitis E virus and rheumatic diseases: what do rheumatologists need to know?[J]. BMC Rheumatol, 2020, 4: 51. DOI: 10.1186/s41927-020-00149-0.
[24]KamarN, DaltonHR, AbravanelF, et al. Hepatitis E virus infection[J]. Clin Microbiol Rev, 2014, 27(1): 116-138. DOI: 10.1128/CMR.00057-13.
[25]PerumpailRB, AhmedA, HigginsJP, et al. Fatal accelerated cirrhosis after imported HEV genotype 4 infection[J]. Emerg Infect Dis, 2015, 21(9): 1679-1681. DOI: 10.3201/eid2109.150300.
[26]KamarN, MansuyJM, CointaultO, et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients[J]. Am J Transplant, 2008, 8(8): 1744-1748. DOI: 10.1111/j.1600-6143.2008.02286.x.
[27]KamarN, GarrousteC, HaagsmaEB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants[J]. Gastroenterology, 2011, 140(5): 1481-1489. DOI: 10.1053/j.gastro.2011.02.050.
[28]WangYJ, ChenGF, PanQW, et al. Chronic hepatitis E in a renal transplant recipient: the first report of genotype 4 hepatitis E virus caused chronic infection in organ recipient[J]. Gastroenterology, 2018, 154(4): 1199-1201. DOI: 10.1053/j.gastro.2017.12.028.
[29]WangYJ, LiuSH, PanQW, et al. Chronic hepatitis E in an immunocompetent patient[J]. Clin Res Hepatol Gastroenterol, 2020, 44(3): e66-e68. DOI: 10.1016/j.clinre.2019.08.001.
[30]LampejoT, CurtisC, IjazS, et al. Nosocomial transmission of hepatitis E virus and development of chronic infection: The wider impact of COVID-19[J]. J Clin Virol, 2022, 148: 105083. DOI: 10.1016/j.jcv.2022.105083.
[31]BorentainP, ColsonP, BolonE, et al. Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis[J]. Hepatology, 2018, 67(1): 446-448. DOI: 10.1002/hep.29508.
[32]WuJ, XiangZ, ZhuCX, et al. Extrahepatic manifestations related to hepatitis E virus infection and their triggering mechanisms[J]. J Infect, 2021, 83(3): 298-305. DOI: 10.1016/j.jinf.2021.07.021.
[33]DaltonHR, KamarN, Van EijkJJ, et al. Hepatitis E virus and neurological injury[J]. Nat Rev Neurol, 2016, 12(2): 77-85. DOI: 10.1038/nrneurol.2015.234.
[34]SoodA, MidhaV, SoodN. Guillain-Barre syndrome with acute hepatitis E[J]. Am J Gastroenterol, 2000, 95(12): 3667-3668. DOI: 10.1111/j.1572-0241.2000.03409.x.
[35]WangYJ, WangS, WuJ, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: a large prospective case-control study in China[J]. The Lancet EBioMedicine, 2018, 36: 122-130. DOI: 10.1016/j.ebiom.2018.08.053.
[36]KamarN, WeclawiakH, Guilbeau-FrugierC, et al. Hepatitis E virus and the kidney in solid-organ transplant patients[J]. Transplantation, 2012, 93(6): 617-623. DOI: 10.1097/TP.0b013e318245f14c.
[37]WoolsonKL, ForbesA, VineL, et al. Extra-hepatic manifestations of autochthonous hepatitis E infection[J]. Aliment Pharmacol Ther, 2014, 40(11-12): 1282-1291. DOI: 10.1111/apt.12986.
[38]JainAK, SircarS, JainM, et al. Increased morbidity in acute viral hepatitis with glucose-6-phosphate dehydrogenase deficiency[J]. Indian J Gastroenterol, 2013, 32(2): 133-134. DOI: 10.1007/s12664-012-0226-9.
[39]ThapaR, PramanikS, BiswasB, et al. Hepatitis E virus infection in a 7-year-old boy with glucose 6-phosphate dehydrogenase deficiency[J]. J Pediatr Hematol Oncol, 2009, 31(3): 223-224. DOI: 10.1097/MPH.0b013e3181984dab.
[40]AuWY, ChanSC. Association between glucose 6-phosphate dehydrogenase (G6PD) deficiency and fatal outcome of hepatitis E infection in middle-aged men[J]. Singapore Med J, 2012, 53(2): 148-149. DOI:.
[41]AuWY, NgaiCW, ChanWM, et al. Hemolysis and methemoglobinemia due to hepatitis E virus infection in patient with G6PD deficiency[J]. Ann Hematol, 2011, 90(10): 1237-1238. DOI: 10.1007/s00277-011-1167-6.
[42]ShahSA, LalA, IdreesM, et al. Hepatitis E virus-associated aplastic anaemia: the first case of its kind[J]. J Clin Virol, 2012, 54(1): 96-97. DOI: 10.1016/j.jcv.2012.02.002.
[43]ChoudharySK, AgarwalA, MandalRN, et al. Hemophagocytic lymphohistiocytosis associated with hepatitis A and hepatitis E co-infection[J]. Indian J Pediatr, 2016, 83(6): 607-608. DOI: 10.1007/s12098-015-2021-y.
[44]MuyldermansA, Van DroogenbroeckJ, DescheemaekerP, et al. Hepatitis E virus-associated haemophagocytic lymphohistiocytosis[J]. Acta Clin Belg, 2021, 76(4): 314-317. DOI: 10.1080/17843286.2020.1733179.
[45]WedemeyerH, RybczynskaJ, PischkeS, et al. Immunopathogenesis of hepatitis E virus infection[J]. Semin Liver Dis, 2013, 33(1): 71-78. DOI: 10.1055/s-0033-1338118.
[46]European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection[J]. J Hepatol, 2018, 68(6): 1256-1271. DOI: 10.1016/j.jhep.2018.03.005.
[47]PischkeS, HardtkeS, BodeU, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience[J]. Liver Int, 2013, 33(5): 722-726. DOI: 10.1111/liv.12114.
[48]KamarN, IzopetJ, TriponS, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients[J]. N Engl J Med, 2014, 370(12): 1111-1120. DOI: 10.1056/NEJMoa1215246.
[49]KamarN, AbravanelF, BehrendtP, et al. Ribavirin for hepatitis E virus infection after organ transplantation: a large European retrospective multicenter study[J]. Clin Infect Dis, 2020, 71(5): 1204-1211. DOI: 10.1093/cid/ciz953.
[50]Peters Van TonAM, GeversTJ, DrenthJP. Antiviral therapy in chronic hepatitis E: a systematic review[J]. J Viral Hepat, 2015, 22(12): 965-973. DOI: 10.1111/jvh.12403.
[51]KamarN, SelvesJ, MansuyJM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients[J]. N Engl J Med, 2008, 358(8): 811-817. DOI: 10.1056/NEJMoa0706992.
[52]BertuzzoVR, RavaioliM, MorelliMC, et al. Pregnant woman saved with liver transplantation from acute liver failure due to hepatitis E virus[J]. Transpl Int, 2014, 27(9): e87-89. DOI: 10.1111/tri.12305.
[53]DrinaneM, Jing WangX, WattK. Sofosbuvir and ribavirin eradication of refractory hepatitis E in an immunosuppressed kidney transplant recipient[J]. Hepatology, 2019, 69(5): 2297-2299. DOI: 10.1002/hep.30428.
[54]DonnellyMC, ImlachSN, AbravanelF, et al. Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV viremia and restore reactive T cells in a HEV/HCV co-infected liver transplant recipient[J]. Gastroenterology, 2017, 152(1): 300-301. DOI: 10.1053/j.gastro.2016.05.060.
[55]TodescoE, DemeretS, CalinR, et al. Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin[J]. AIDS, 2017, 31(9): 1346-1348. DOI: 10.1097/QAD.0000000000001474.
[56]Van Der ValkM, ZaaijerHL, KaterAP, et al. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection[J]. J Hepatol, 2017, 66(1): 242-243. DOI: 10.1016/j.jhep.2016.09.014.
[57]SchulzM, PappCP, BockCT, et al. Combination therapy of sofosbuvir and ribavirin fails to clear chronic hepatitis E infection in a multivisceral transplanted patient[J]. J Hepatol, 2019, 71(1): 225-227. DOI: 10.1016/j.jhep.2019.03.029.
[58]MarionO, AbravanelF, IzopetJ, et al. Failure to respond to ribavirin despite elevated intra-erythrocyte zinc level in transplant-patients with chronic hepatitis E virus infection[J]. Transpl Infect Dis, 2019, 21(2): e13050. DOI: 10.1111/tid.13050.